Immunic receives notice of allowance for united states patent protecting vidofludimus calcium's dose strengths in progressive multiple sclerosis

– fifth u.s. patent directed to use of vidofludimus calcium in multiple sclerosis – – comprehensive intellectual property strategy secures protection into 2041 in the u.s., unless extended further – new york , sept. 9, 2025 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has received a notice of allowance from the united states patent and trademark office (uspto) for patent application 18/529,946, entitled, "treatment of multiple sclerosis comprising dhodh inhibitors.
IMUX Ratings Summary
IMUX Quant Ranking